

Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate

To the Editor,

Monoclonal anti-tumor IgG antibodies are used widely to treat malignancies. Studies in the field of AllergoOncology, focusing on the interactions between IgE, allergy, and cancer, point to biological characteristics of IgE that may engender potent anti-tumor functions.¹ These include superior affinity of IgE for cognate Fc receptors and the presence in tumors of effector cell populations (eg, macrophages and mast cells) known to exert anti-tumor activities when activated by IgE.^{2,3} Following promising preclinical findings,^{2,4} MOv18 IgE, specific for the tumor-associated antigen folate receptor alpha (FR α), overexpressed in ovarian and basal breast cancers and other solid tumors,⁵ is the first anti-cancer IgE antibody studied in a first-in-class, first-in-human clinical trial (ClinicalTrials.gov Identifier: NCT02546921).

One of the potential concerns associated with application of IgE as a therapy in the clinic relates to the perceived risk of IgE-mediated anaphylaxis. Safety evaluation of such a novel agent mandated the development of bespoke methods to monitor potential hypersensitivity reactions following intravenous infusion and ideally also to help in predicting such a reaction when selecting patients for treatment. Over the past 15 years, the basophil activation test (BAT) has been developed and widely employed to study and predict type 1 hypersensitivity reactions to food, venom, and drugs in the allergy field.^{6,7} Thus far, its use in the context of cancer is limited to a small number of studies for the detection of allergic reactions to chemotherapeutic agents.⁸ Basophil activation in the context of tumor-associated immunomodulation and in often heavily treated patients has not been well-studied.

Employing the BAT in whole blood of 42 ovarian cancer patients with diverse treatment histories and tumor histologies, we examined the propensity of human basophils to be activated by anti-cancer IgE ex vivo. We first identified circulating basophils (CCR3^{high}SSC^{low}; gating strategy in Figure S1A) from patients with cancer. Basophils were activated (up-regulation of CD63 expression) ex vivo by IgE- and non-IgE-mediated triggers (anti-Fc ϵ RI, anti-IgE, and fMLP, Figure 1A, Figure S1B). Consistent with previously reported findings in allergic cohorts,⁶ levels of basophil activation varied among individuals. We detected no basophil activation following addition

of the hapten-specific NIP (4-hydroxy-3-iodo-5-nitrophenylacetic acid) IgE alone or its multivalent antigen (NIP-BSA) alone. However, we detected basophil activation by exogenous stimulation of the hapten-specific NIP IgE in combination with multimeric NIP-BSA (Figure 1A). This suggested that IgE could recognize unoccupied cell surface Fc ϵ RI on basophils ex vivo and basophils could be activated by exogenous Fc ϵ RI receptor engagement and formation of cross-linking immune complexes.

We then examined whether stimulation with the anti-cancer mouse/human chimeric IgE antibody (MOv18) could trigger ex vivo basophil activation (Figure 1B, C). As expected in this cohort ($n = 42$), stimulation with anti-Fc ϵ RI, anti-IgE, and fMLP (positive controls) triggered CD63 up-regulation. In all but one patient sample, no basophil activation was measured following incubation of ovarian cancer patient blood with MOv18 IgE or control non-FR α -reactive IgE in the absence of any additional exogenous cross-linking stimulus (mean fold change in %CD63: 1.4 for MOv18 IgE, 1.3 for control IgE; 7.5 and 10.6, respectively, in the positive responder) (Figure 1D). Activation, or lack thereof, was irrespective of different patient tumor histologies and treatment histories, that is, (a) treatment-naïve patients ($n = 7$), (b) following primary debulking surgery ($n = 8$), (c) following surgery and chemotherapy ($n = 21$), or (d) following treatment with bevacizumab ($n = 7$) (Figure 1E, F). Neither MOv18 IgE nor control non-FR α -reactive IgE triggered basophil activation in the blood of a patient with already raised serum tryptase, a marker which could indicate mastocytosis (although this clinical information was not available) and may have potentially predisposed this individual to an increased risk of hypersensitivity to IgE stimulation, including to MOv18 IgE (Figure 1G).

Since MOv18 IgE recognizes the tumor-associated antigen, FR α , it is possible that FR α shed from cancer cells in tissues and anti-FR α autoantibodies (autoAbs), if present in patient circulation, could form immune complexes with MOv18 IgE. This may result in Fc ϵ RI cross-linking and basophil activation (Figure 2A). No CD63 up-regulation on basophils was measured following ex vivo stimulation with either MOv18 IgE or control IgE in any sample from patients with known tumor FR α expression status, as determined by immunohistochemistry (Figure 2B, C, Table S1).

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. *Allergy* published by John Wiley & Sons Ltd.




FIGURE 1 Anti-cancer IgE does not trigger basophil activation in 98% of cancer patient blood samples studied. Basophil activation (fold change in % CD63 expression) was evaluated following stimulation with anti-FcεRI antibody, anti-IgE antibody, and fMLP (positive controls) and cross-linking of NIP IgE by multimeric NIP-BSA (A). No basophil activation (<3.0 fold change of % CD63-positive basophils, dotted cutoff line) was triggered by MOv18 or control IgE in all but one specimen, despite activation by positive controls (B-D), and irrespective of previous standard treatments received (E, F), nor when measured in the blood of a patient with already raised serum tryptase (G)




FIGURE 2 FRα-positivity in blood or tumor does not influence basophil activation by anti-cancer IgE. Circulating FRα and anti-FRα autoantibodies may form immune complexes with MOv18 IgE, triggering basophil activation (A). No basophil activation was measured following MOv18 IgE stimulation in blood from the 71% of patients with FRα-positive tumor (B) (representative FRα-stained paraffin-embedded tumor, C). Despite detectable FRα or anti-FRα IgG autoantibodies in a proportion of patients, MOv18 IgE triggered basophil activation in one blood sample (D-G). In the 9% of patients with both FRα and anti-FRα IgG autoantibodies, no basophil activation by MOv18 IgE or control IgE was observed (H)

Anti-FR α IgE autoAbs were not detectable in patient serum (Table S1). Although serum FR α and anti-FR α IgG autoAbs were measurable in 44% and 21% of patients, respectively (Figure 2D, F, Table S1), basophils in 41 of 42 matched unfractionated blood samples were not activated by incubation with MOv18 or control IgE (Figure 2E, G). MOv18 IgE combined with monovalent recombinant FR α did not trigger activation (Figure S1C). Moreover, no MOv18 IgE-mediated activation was measured in those 9% of patients with both measurable serum FR α and IgG autoAbs against FR α , or in the blood from 2 of the 3 patients who additionally had FR α -positive tumor (Figure 2H, Table S1). Basophil activation by MOv18 IgE was observed in only one patient. In this patient's blood sample, we measured circulating FR α but no anti-FR α autoAbs. The patient's tumor FR α expression status was unknown, and serum tryptase levels were not elevated (7 ng/mL; Table S1). In the same patient, CD63 up-regulation was also triggered by the control non-FR α -reactive IgE. Together, these suggested that basophil activation in this specimen may involve a non-FR α -specific mechanism, potentially through a humoral response directed toward the antibody's structural components. The prevalence of such a propensity to activate basophils in ovarian cancer and other patient cohorts and its potential clinical significance require further in-depth investigations. Such studies may consider the possible cross-linking by autoAbs, such as those recognizing alpha-gal (galactose- α -1,3-galactose) previously associated with hypersensitivity to cetuximab, an anti-EGFR IgG antibody,⁹ or by anti-drug antibodies (ADAs) that may develop following MOv18 IgE treatment.

In conclusion, the basophil activation test showed no reactivity with MOv18 or control IgE in 41 of 42 ovarian cancer patients' samples. Combined with measurements of other clinical and biological parameters, application of BAT to the clinical study of a first-in-class IgE in cancer patients (ClinicalTrials.gov Identifier: NCT02546921) may allow correlations with clinical observations, to help monitor and potentially predict patient safety.

KEYWORDS

basophils, BAT, IgE, MOv18, ovarian cancer

ACKNOWLEDGMENTS

We thank all patients who participated in this study and colleagues from Guy's and St Thomas' Oncology & Haematology Clinical Trial team, especially Ms Agnieszka Zielonka, Ms Harriet Gilbert-Jones, Ms Malahat Khaula, and Dr Sara Lombardi for their assistance. We are grateful to Prof. Silvana Canevari and Dr Mariangela Figini, IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy, for provision of materials and advice. We acknowledge the Biomedical Research Centre (BRC) Immune Monitoring Core Facility team at Guy's and St Thomas' NHS Foundation Trust for flow cytometry facilities and assistance and Ms Debbie Finch at the Cancer Research UK King's Health Partners Centre at King's College London for immunohistochemistry support.

CONFLICTS OF INTEREST

SNK and JFS are founders and shareholders of IGEM Therapeutics Ltd., and HJB is now employed through a fund provided by IGEM Therapeutics Ltd. CB is a freelance pharmaceutical physician/medical advisor with Barton Oncology Ltd and in addition to work with Cancer Research UK Centre for Drug Development has undertaken consultancy work with many companies including in the last ~5 years, Astex Therapeutics Ltd, BerGen Bio A/S, Cancer Targeting Systems Inc, CellCentric Ltd, Certara LP, EngMab AG, Inbiomotion SL, Innate Pharma SA, Macrophage Pharma Ltd, MorphoSys AG, Mosaic Biomedicals SL, Norgine Pharmaceuticals Ltd, Ono Pharma UK Ltd, Orion Clinical Services Ltd, PIQUR Therapeutics AG, PTEN Research Foundation, SFL Services GmbH, Shionogi Ltd, T3 Pharmaceuticals AG, UCB Biopharma SPRL, and the Wellcome Trust Ltd. CB is on the advisory board for SFL Services GmbH and owns shares in GlaxoSmithKline. All other authors have declared no conflict of interest.

FUNDING INFORMATION

The authors acknowledge support from Cancer Research UK (C30122/A11527; C30122/A15774); the Academy of Medical Sciences; CRUK//NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587), the Inman Charity, the Medical Research Council (MR/L023091/1), the Cancer Research UK King's Health Partners Centre at King's College London, and Breast Cancer Now (147) working in partnership with Walk the Walk. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS-BRC-1215-20006). The authors are solely responsible for study design, data collection, analysis, decision to publish, and preparation of the manuscript. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

ETHICAL APPROVAL

This study has been reviewed and approved by Guy's Research Ethics Committee (Reference 09/H0804/45).

KEYWORDS

basophils, BAT, IgE, MOv18, ovarian cancer

Heather J. Bax^{1,2} 

Atousa Khiabany^{1,2}

Chara Stavraka^{1,2,3}

Giulia Pellizzari¹

Charleen Chan Wah Hak^{1,3}

Alexandra Robinson¹

Kristina M. Ilieva^{1,4}

Natalie Woodman⁵

Cristina Naceur-Lombardelli⁵

Cheryl Gillett⁵

Sarah Pinder⁵

Hannah J. Gould^{6,7}
 Christopher J. Corrigan^{7,8}
 Stephen J. Till^{7,8}
 Sidath Katugampola⁹
 Claire Barton^{9,10}
 Anna Winship³
 Sharmistha Ghosh³
 Ana Montes³
 Debra H. Josephs^{1,2,3}
 James F. Spicer^{2,3}
 Sophia N. Karagiannis^{1,4} 

London, 9th Floor, Tower Wing, Guy's Hospital, London, SE1
 9RT, United Kingdom.
 Email: sophia.karagiannis@kcl.ac.uk

ORCID

Heather J. Bax  <https://orcid.org/0000-0003-0432-4160>
 Sophia N. Karagiannis  <https://orcid.org/0000-0002-4100-7810>

REFERENCES

1. Jensen-Jarolim E, Bax HJ, Bianchini R, et al. AllergoOncology - the impact of allergy in oncology: EAACI position paper. *Allergy*. 2017;72(6):866-887.
2. Josephs DH, Bax HJ, Dodev T, et al. Anti-folate receptor-alpha IgE but not IgG recruits macrophages to attack tumors via TNFalpha/MCP-1 signaling. *Cancer Res*. 2017;77(5):1127-1141.
3. Pellizzari G, Hoskin C, Crescioli S, et al. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. *EBioMedicine*. 2019;43:67-81.
4. Josephs DH, Nakamura M, Bax HJ, et al. An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE. *Allergy*. 2018;73(12):2328-2341.
5. Cheung A, Opzoomer J, Ilieva KM, et al. Anti-folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast cancer. *Clin Cancer Res*. 2018;24(20):5098-5111.
6. Santos AF, Douiri A, Becares N, et al. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. *J Allergy Clin Immunol*. 2014;134(3):645-652.
7. Erdmann SM, Sachs B, Kwiecien R, Moll-Slodowy S, Sauer I, Merk HF. The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy. *Allergy*. 2004;59(10):1102-1109.
8. Giavina-Bianchi P, Galvao VR, Picard M, Caiado J, Castells MC. Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy. *J Allergy Clin Immunol Pract*. 2017;5(3):728-736.
9. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. *N Engl J Med*. 2008;358(11):1109-1117.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

¹St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, London, UK

²School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK

³Departments of Medical Oncology and Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK

⁴Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, Guy's Cancer Centre, King's College London, London, UK

⁵King's Health Partners Cancer Biobank, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK

⁶Randall Centre for Cell and Molecular Biophysics, School of Basic and Medical Biosciences, King's College London, London, UK

⁷Asthma UK Centre, Allergic Mechanisms in Asthma, King's College London, London, UK

⁸Department of Respiratory Medicine and Allergy and School of Immunology and Microbial Sciences, King's College London, London, UK

⁹Centre for Drug Development, Cancer Research UK, London, UK

¹⁰Barton Oncology Ltd, Eastcote, UK

Correspondence

Sophia N. Karagiannis, St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College

Supporting Information:

Bax et al., Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate

Supplementary Methods***Ovarian cancer patient study***

Women with ovarian cancer were enrolled into the study by written informed consent. Peripheral venous blood samples were drawn into BD Vacutainer™ Hemogard Closure Plastic K2-EDTA Tubes (BD). Serum samples were prepared by drawing blood into SST Clot Activator and Polymer Gel Hemogard Closure Blood Tubes (BD), followed by centrifugation of clotted blood at 2500RPM for 15 minutes at 4°C, careful pipetting of serum and storage at -80°C. Demographic characteristics, including tumor histology and prior treatment history, were obtained from clinical databases, anonymized and analyzed in conjunction with clinical samples.

Basophil Activation Test (BAT)

The basophil activation test (BAT) was performed within 4 hours of blood collection using the Flow2 CAST® kit (Bühlmann) as per instructions, except that incubation time with stimuli was optimized from the recommended 10 minutes to 30 minutes. Briefly, unfractionated whole blood was incubated with stimulation buffer (Bühlmann), and different stimuli: anti-FcεRI (Bühlmann), anti-IgE antibody (Dako) or fMLP (Bühlmann), or anti-FRα antibody, MOv18 IgE or control non-FRα-reactive IgE antibodies (at 3.5 µg/ml, prepared in-house). In the case of hapten-specific anti-NIP IgE, cross-linking with NIP-BSA (at 20 µg/ml, 5 NIP to BSA ratio, in-house) was included. Monovalent recombinant FRα (R&D Systems) was added, at indicated concentrations, to some MOv18 IgE stimulations. All conditions were then stained with anti-CCR3-PE and anti-CD63-FITC staining cocktail (Bühlmann) and incubated at 37°C for 30 minutes in a 5% CO₂ incubator. For all preparations, red blood cell lysis was then performed with diluted lysis buffer (Bühlmann) for 10 minutes at room temperature, followed by centrifugation and resuspension of cell pellets with acquisition buffer (Bühlmann). Flow cytometric evaluations were performed with a FACSCanto™ II using FACSDiva software (BD). Basophil activation was expressed as the fold change in % CD63-positive CCR3-PE^{high}SSC^{low} basophils over the background control (stimulation buffer and staining antibody cocktail alone) for each sample¹. The % CD63 expression (without fold change calculation) is also shown in Figure S1B. All data analyses were performed, and representative plots prepared using FlowJo™ software (FlowJo LLC).

Tumor FRα expression status by immunohistochemistry (IHC)

For a subset of patients, tumor sections from primary debulking surgery were evaluated for FRα expression status. Novocastra™ Liquid mouse anti-human FRα primary antibody (Leica) was

Supporting Information:

Bax et al., Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate

applied to formalin-fixed, paraffin-embedded tumor sections (from primary debulking surgery) for 32 minutes at room temperature at 1/500 dilution, followed by detection with Ultra Universal 3,3'-diaminobenzidine (DAB) detection kit (Ventana Medical Systems Inc.) and then Haematoxylin II applied for 8 minutes. This protocol was performed using the BenchMark ULTRA automated immunohistochemistry/in situ hybridisation (IHC/ISH) slide staining system (Ventana Medical Systems Inc.), with an extended cell conditioning 2 (CC2) solution antigen retrieval.

Circulating FR α and anti-FR α autoantibody ELISAs

ELISAs were performed as previously described². Circulating FR α (e.g. shed from tumor tissues) or anti-FR α autoantibodies in ovarian patient serum samples were evaluated by first coating 96-well MaxiSORP™ plates (Nunc) with 100 μ l/well of 2 μ g/ml monoclonal mouse anti-human FR α IgG1 antibody (clone 548908) or 1 μ g/ml recombinant FR α , respectively (both R&D Systems and diluted in 0.2M carbonate-bicarbonate buffer, Pierce). Following incubation at 4°C, overnight, plates were blocked with 250 μ l/well SuperBlock™ (Perbio Science Ltd.) for 2 hours at room temperature and then washed 4 times with 250 μ l/well PBS-0.05% Tween® 20 solution (Severn Biotech and Sigma, respectively). Serum samples were diluted to 20% (or to 50% for IgE autoantibodies) in a 50:50 solution of SuperBlock™ and PBS-0.05% Tween® 20. Standard curves of recombinant FR α (R&D Systems), or anti-FR α human IgG or IgE monoclonal antibody (prepared in house) were diluted in SuperBlock™-PBS-0.05% Tween® 20, supplemented with 20% human serum albumin (type AB male, Sigma). Samples and standards were added 50 μ l/well, in triplicate, and incubated for 2 hours at room temperature, followed by 4 washes. FR α was detected by 50 μ l/well addition of biotinylated polyclonal goat anti-human FR α IgG1 antibody (R&D Systems, diluted to 25 ng/ml in SuperBlock™-PBS-0.05% Tween® 20) for 2 hours at room temperature, 4 further washes, and 50 μ l/well addition of streptavidin-peroxidase conjugate (Pierce, diluted 1/22000 in SuperBlock™-PBS-0.05% Tween® 20) for 30 minutes at room temperature. Anti-FR α IgG autoantibodies were detected by 50 μ l/well addition of HRP-conjugated polyclonal goat anti-human Fc γ -specific F(ab')₂ fragment (Jackson Immuno Research, diluted 1/500 in SuperBlock™-PBS-0.05% Tween® 20) for 45 minutes at room temperature. Anti-FR α IgE autoantibodies were detected by 50 μ l/well addition of HRP-conjugated polyclonal goat anti-human IgE antibody (Sigma, diluted 1/500 in SuperBlock™-PBS-0.05% Tween® 20) for 2 hours at room temperature. Plates were then washed 5 times and developed by 50 μ l/well addition of OPD (Sigma) diluted to 0.5 mg/ml in stable peroxidase

Supporting Information:

Bax et al., Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate

substrate buffer (Pierce) for 5-10 minutes, at room temperature, in darkness, followed by 50 µl/well 1M HCl solution (Sigma). Using a Fluostar Omega microplate reader (BMG LABTECH), FRα and anti-FRα IgG autoantibodies were measured using an absorbance 492nm, with a correction wavelength of 650nm. Standard curves were fitted using a 4-point variable curve-fitting program using a minimum of 6 points (MARS software, BMG LABTECH). The lower limit of quantification (LLOQ) was 6.25 ng/ml, 3.125 ng/ml, and 5 ng/ml for FRα, anti-FRα IgG, and anti-FRα IgE, respectively. Values below LLOQ are reported as 0 ng/ml.

Statistical Analyses

All statistical analyses were performed in GraphPad Prism (GraphPad Software, Inc.). Datasets were compared by t-test or one-way ANOVA with Kruskal-Wallis multiple comparisons. P values were represented as follows: *=P<0.05, **=P<0.01, ***=P<0.001, ****=P<0.0001. Error bars represent Standard Error of Mean (SEM).

References

1. Fernandez TD, Ariza A, Palomares F, et al. Hypersensitivity to fluoroquinolones: The expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone. *Medicine (Baltimore)*. 2016;95(23):e3679.
2. Rudman SM, Josephs DH, Cambrook H, et al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcγεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. *Clin Exp Allergy*. 2011;41(10):1400-1413.

Supporting Information:

Bax et al., Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate




Figure S1– (A) Basophil Activation Test (BAT) gating strategy. As per instructions for the Flow2 CAST[®] kit (Bühlmann), basophils in unfractionated whole blood samples were gated as CCR3^{high}SSC^{low}. Up-regulation of CD63 on the surface of basophils was monitored as a marker of *ex vivo* basophil activation; **(B) Basophil Activation Test (BAT) % CD63 expression without fold change calculation;** **(C) MOV18 IgE combined with recombinant FRα does not trigger basophil activation in patient blood.** No basophil CD63 up-regulation was measured following *ex vivo* stimulation with MOV18 IgE, plus monovalent recombinant FRα at concentrations up to 13.3 μg/ml, 500-fold higher than those measured physiologically in ovarian cancer patient circulation (highest FRα 25.13 ng/ml measured in our cohort (Figure 2D, Table S1)).

Supporting Information:

Bax et al., Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate

Table S1 – Ovarian cancer patient characteristics.

	FR α status				BAT Fold change in %CD63	
	Tumor FR α expression	sFR α (ng/ml)	Anti-FR α IgG autoAb (ng/ml)	Anti-FR α IgE autoAb (ng/ml)	MOv18 IgE	Control non-FR α -reactive IgE
1	Positive	7.19	0.00	-	1.9	-
2	Negative	7.58	6.71	-	0.8	-
3	-	11.42	0.00	-	1.0	-
4	-	25.13	0.00	-	2.9	-
5	-	0.00	0.00	-	-	-
6	-	0.00	0.00	-	1.2	-
7	-	0.00	3.90	-	2.2	-
8 [†]	Positive	0.00	9.57	-	-	-
9	-	19.47	0.00	0.00	7.5	10.6
10	-	11.90	4.10	0.00	0.9	-
11	Positive	13.19	0.00	0.00	0.6	-
12	Negative	0.00	0.00	0.00	0.6	-
13	Positive	20.52	6.13	0.00	0.7	-
14 [†]	Positive	0.00	7.23	-	-	-
15	Negative	0.00	0.00	0.00	0.4	0.7
16 [†]	-	0.00	0.00	0.00	-	-
17	-	0.00	6.96	0.00	1.2	2.2
18	-	0.00	0.00	0.00	2.4	1.8
19	Negative	6.51	0.00	0.00	0.4	0.2
20	Positive	0.00	0.00	0.00	0.3	0.2
21	-	0.00	0.00	0.00	0.2	0.2
22	-	0.00	0.00	0.00	1.5	1.3
23	Negative	0.00	0.00	0.00	0.7	1.2
24	-	0.00	0.00	0.00	1.3	2.0
25	-	0.00	0.00	0.00	2.6	0.8
26	-	0.00	0.00	0.00	0.8	0.4
27	-	0.00	0.00	0.00	0.6	0.3
28	-	0.00	0.00	0.00	1.2	0.7
29	Positive	14.75	0.00	0.00	0.9	1.3
30	-	-	-	-	0.8	0.6
31	-	12.67	0.00	-	1.6	1.5
32	-	15.16	0.00	-	0.7	0.7
33	Positive	13.54	0.00	-	-	-
34	-	-	-	-	0.8	1.2
35	-	-	-	-	0.3	0.6
36	Positive	-	-	-	1.6	1.4
37	Positive	17.95	0.00	-	0.4	0.3
38	Positive	10.99	0.00	-	2.7	1.4
39	-	-	-	-	1.8	1.0
40	-	-	-	-	1.6	0.9
41	-	-	-	-	1.9	1.5
42 [‡]	Positive	-	-	-	1.3	1.4

[†]Non-responder' patients, [‡]Patient with elevated serum tryptase (33 ng/ml; ULN = 14 ng/ml). –Not tested.